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Background: Cancer stem cells (CSCs) have been reported to play an important role in chemoradiation resistance.
Although the association of CSC markers with clinicopathological outcomes after neoadjuvant chemoradiotherapy
(NACRT) has been reported in various types of cancers, there have been no such reports for pancreatic cancer. Here
we examined the sequential changes in CSC marker expressions after NACRT in patients with pancreatic
adenocarcinoma (PA) and the impact of these changes on the prognosis.
Methods: We used immunohistochemistry to evaluate the expressions of the CSC markers epithelial cell adhesion
molecule (EpCAM), CD24, CD44, CD133, CXCR4 and Aldehyde dehydrogenase 1 (ALDH1) in resected specimens
obtained from 28 PA patients, and we compared these expressions with the patients’ clinicopathological
parameters and survival data.
Results: The expression frequencies of CD44 and ALDH1 were significantly higher in the NACRT group (n = 17)
compared to the non-NACRT group (n = 11), but the CD133 expression was significantly lower in the NACRT
group. In the NACRT group, the expression of CD133 was inversely correlated with that of ALDH1, and CD133
+/ALDH1− expression was associated with an unfavorable patient outcome.
Conclusion: This is the first report showing that NACRT may influence the expression frequencies of CD44, CD133
and ALDH1 in PA patients. Moreover, CD133 and ALDH1 expressions may be useful predictors of prognosis in PA
patients who have received NACRT.
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Pancreatic cancerBackground
Pancreatic cancer is the fourth leading cause of cancer
death in the United States, and its 5-year survival rate is
only 6% [1]. Surgical resection remains the only poten-
tially curative therapeutic option. However, pancreatic
cancer proceeds asymptomatically in many cases, and
surgical resection is feasible in only 10% to 20% of pa-
tients at the time of initial diagnosis [2]. Even after* Correspondence: hkamachi@db3.so-net.ne.jp
†Equal contributors
1Department of Gastoroenterological Surgery I, Graduate School of Medicine,
Hokkaido University, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan
Full list of author information is available at the end of the article
© 2014 Mizukami et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.complete resection, the long-term survival rate remains
very poor [3,4].
New therapeutic strategies are thus needed to improve
the prognosis of pancreatic cancer patients. During the
past decade, neoadjuvant chemoradiotherapy (NACRT)
for locally advanced pancreatic adenocarcinoma has re-
ceived attention [5]. NACRT has several positive aspects
such as an increased resectability rate with clear margins
and decreased rates of metastatic lymph nodes and local
relapse, and NACRT resulted in a significant improve-
ment of the 5-year survival rate in curative cases [6,7].
However, many patients with pancreatic cancer do not
respond to NACRT, and little is known about the potentialral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to NACRT.
Evidence has accumulated indicating that many solid
tumours are driven and managed by rare subpopulations
of cancer stem cells (CSCs). In pancreatic cancer, several
markers have been used to identify CSCs, such as epi-
thelial cell adhesion molecule (EpCAM, also known as
epithelial-specific antigen, or ESA) [8], CD24 [9], CD44
[10,11], CD133 [12,13], CXCR4 [14], aldehyde dehydro-
genase 1 (ALDH1) [15,16] and combinations of these
markers [17-19]. And it has been reported that the ex-
pression of CSCs related to patients prognosis [20]. The
biological roles of each CSCs marker are widely differ-
ent. EpCAM is considered an adhesion molecule. CD24
and CD44 also function as adhesion molecules. CD133
is a cell surface glycoprotein. CXCR4 functions as a che-
mokine receptor. ALDH1 is an intracellular enzyme in-
volved in retinoic acid.
CSCs seem to be primarily responsible for the fre-
quently observed failure of therapies as well as for re-
lapse after anticancer treatment [21]. In fact, there are
several reports of the resistance of CSCs to chemoradia-
tion therapy in head-neck [22], esophageal [23,24], lung
[25] and colon [26] cancer, but there has been no report
on pancreatic CSCs related to chemoradiation resistance,
to our knowledge.
In the present study therefore, we investigated the prop-
erties of pancreatic CSCs to compare the expressions of
CSC markers in the tumours of PA patients according to
whether they received NACRT, and to analyze the associa-
tions between the expressions of the CSC markers and
the clinicopathological characteristics of the NACRT




Between May 2003 and September 2013, 28 PA patients
(14 males, 14 females) underwent surgery at the Depart-
ment of General Surgery I, Hokkaido University Gradu-
ate School of Medicine (Sapporo, Japan). Among them,
17 patients received preoperative chemoradiotherapy
with gemcitabine (GEM) followed by 50.4 Grays (Gy) of
radiation therapy (NACRT group). All patients in the
NACRT group received a cumulative irradiation dose of
50.4 Gy in 28 fractions of 1.8 Gy, using 3-dimensional
radiation therapy. The primary tumour plus regional
lymph nodes were targeted. Systemic GEM 150 mg/m2
was administered weekly. Within 4–6 weeks after the
completion of NACRT, the patients were reassessed
by CT, MRI and PET-CT and surgery was performed.
During the same period, 11 patients did not receive pre-
operative chemoradiotherapy but underwent surgery
(the non-NACRT group).Recurrence was diagnosed on the basis of clinical ex-
aminations and imaging studies. Time to death, final
follow-up examination, and the diagnosis of recurrence
was measured from the date of surgery. Surviving pa-
tients were followed up until March 2014.
Written informed consent was obtained from all 28 pa-
tients prior to their enrollment in the study, and this study
design and protocol were approved by the institutional re-
view board of Hokkaido University Hospital Sapporo,
Japan (Clinical Research approval number 013–0074).
Pathological specimens
Formalin-fixed and paraffin-embedded specimens were
retrieved from the surgical pathology files of the Path-
ology Department of Hokkaido University Hospital. Sec-
tions were cut and stained with hematoxylin-eosin
(H&E) for routine histopathologic examination. Pancre-
atic ductal adenocarcinoma was diagnosed in all speci-
mens. A representative tissue block was selected from
each case to perform immunohistochemical studies.
Immunohistochemistry
The resected tissues were fixed in 10% formalin and embed-
ded in paraffin blocks, and the most representative block
was chosen for each case. Each block was cut into serial 4-
μm-thick sections for staining with H&E and immunohisto-
chemistry for EpCAM, CD24, CD44, CD133, CXCR4 and
ALDH1. Immunohistochemistry was performed using the
EnVision + System-HRP (Dako Japan, Tokyo), and the
protocol was optimized for each antigen (Table 1).
Briefly, the sections were mounted on charged glass
slides, deparaffinized, and rehydrated through a graded
ethanol series. Antigens were retrieved in Dako EnVision
FLEX Target Retrieval Solution using Dako PT Link for
20 min at 97°C according to the manufacturer’s instruc-
tions (Dako Japan). After the blocking of endogenous
peroxidase activity with 0.03% hydrogen peroxide, the
sections were incubated with the primary antibodies
at room temperature for 30 min and then reacted with
a dextran polymer reagent combined with secondary
antibodies and peroxidase for 30 min at room temp-
erature. Specific antigen-antibody reactions were visual-
ized with diaminobenzidine chromogen applied for
10 min. Slides were counterstained with hematoxylin,
dehydrated and mounted.
Non-neoplastic pancreatic tissues on the same slides
as those summarized in Table 1 were defined as internal
positive controls for each antibody [17,19,27-29]. Nega-
tive control tissue sections were prepared by omitting
the primary antibody.
Immunohistochemical evaluation
All assessments were made on the tumour region of the
specimen (×200). Each slide was evaluated independently
Table 1 Primary antibodies used in the immunohistochemistry
Antigen (clone) Location Antibody species Manufacturer (product) Antigen-retrieval solution Dilution Internal positive control
[reference No]
EpCAM (ESA) M Mouse monoclonal Dako (M3525) PH6 ciltrate buffer 1:200 Epithelium of pancreatic ducts,
acinar cells and islets of
Langerhans cells [29]
CD24 M Mouse monoclonal Neomarkers (MS-1279) PH6 ciltrate buffer 1:50 Acinar cells [27]
CD44 M Mouse monoclonal Abcam(ab51037) PH6 ciltrate buffer 1:50 Acinar cells [28]
CD133 M Rabbit polyclonal Abnova(12663) PH9 Tris EDTA buffer 1:50 Acinar cells [19]
CXCR4 M Mouse monoclonal Zymed(35-8800) PH6 ciltrate buffer 1:50 Acinar cells [17]
ALDH1 C Mouse monoclonal Abcam(ab52492) PH6 ciltrate buffer 1:100 Acinar cells and islets of
Langerhans cells [19]
M: membrane C: cytoplasm.







Age(mean ± SD) 59.9 ± 7.9 63.6 ± 10.4 0.287*1
Gender(male/female) 8/9 6/5 1.000*2
Operative procedures PD/DP/TP 13/3/1 10/1/0 1.000*2
Portal vein resection 70.6% (12/17) 63.6% (7/11) 1.000*2
cT(1/2/3/4) 0/0/17/0 0/0/11/0 1.000*2
cN(0/1) 11/6 6/5 0.701*2
pT(0/1/2/3/4) 0/1/16/0 0/0/11/0 1.000*2








SD: standard deviation; PD: pancreatoducdenectomy; DP: distal pancreatectomy;
TP total pancreatectomy. *1: Unpaired t-test. *2: Fisher’s exact test.
Mizukami et al. BMC Cancer 2014, 14:687 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/687by two independent observers (authors TM and TM),
who did not know the clinical outcomes, and discrepan-
cies between the observers were resolved using a con-
ference microscope. To take into account intratumoral
heterogeneity of antigen expression, we selected two to
six visual fields from different areas of invasive ductal
carcinoma excluding that of intraepithelial neoplasia in
each slide. In detail, guided by the microscope, the areas
were selected randomly per section using a × 4 objective
and a × 10 ocular lens on each H-E staining slide and
marked it by circling each area. And then, we superim-
posed the slide which was stained with CSCs markers
on the HE staining slide, and have marked it by tracing
the mark for evaluation of the immunoreacting score
(IRS). The immunoreaction for each antibody was eval-
uated in each case based on both the proportion of
positive-stained tumour cells and the staining intensity
of the tumour cells . The expression site of each anti-
body (membrane or cytoplasm) is given in Table 1. The
expression of each antibody was evaluated for each
tissue sample by calculating the total IRS as the product
of the proportion and intensity scores according to
previous reported criteria [22]. Briefly, the proportion
score reflected the estimated fraction of positive-stained
tumour cells (0, none; 1, 1%–10%; 2, 11%–50%; 3,
51%–80%; 4, 81%–100%). The intensity score repre-
sented the estimated staining intensity (0, no staining;
1, weak; 2, moderate; 3, strong). The total IRS ranged
from 0 to 12, and the scores were averaged. A positive
expression of each antibody was defined as an averaged
score > median.
Statistical analysis
We used a t-test or Fisher’s exact test to evaluate the
differences in clinicopathological and immunohistologi-
cal features between the NACRT and non-NACRT
group. We tested the associations between clinicopatho-
logical and immunohistologically detected stem cell
marker expressions by Fisher’s exact test. Survival curvesof patients were drawn by the Kaplan- Meier method.
Differences in survival curves were analyzed by the log-
rank test. Differences at P < 0.05 were considered signifi-
cant. All statistical analyses were performed using JMP
Pro 10 (SAS Institute Japan).
Results
Patient characteristics
The patient demographics are shown in Table 2. T-factor,
N-factor, Histological classification and R-factor were
assigned according to the TNM classification of the Union
Internationale Contre le Cancer (UICC 7th edition). There
were no significant differences between the NACRT and
non-NACRT groups in age, gender, operative procedures,
portal vein resection, clinical T, N factor, pathological T, N
factor, histological classification, or residual tumour.
In the evaluation of tumour destruction, over 50% of
the cancer cells had degenerated in nine patients.
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The expressions of EpCAM, CD24, CD44, CD133, and
CXCR4 antigens were membranous in carcinoma cells
(Figure 1A–E).
The IRS of cancer cells with membranous EpCAM ex-
pression ranged from 0 to 12 (median 7.3). Using the cut-
off point, of the 28 cases, 15 (53.6%) were considered
positive. The IRS of the cancer cells with membranous
CD44 expression ranged from 0 to 12 (median 3.4), with
16/28 (57.1%) cases considered positive. The IRS of the
cancer cells with membrane CD24 expression ranged from
0 to 12 (median 2.9), with 10/28 (35.7%) cases being posi-
tive. The IRS of the cancer cells with membrane CD133
expression ranged from 1 to 12 with a median value of
5.7, and 15/28 (53.6%) cases were considered positive for
CD133. The IRS of the cancer cells with membranousFigure 1 Immunohistochemical staining of each CSC marker in pancr
of EpCAM (A), CD24 (B), CD44 (C), CD133 (D), CXCR4 (E) and ALDH1 (F). SCXCR4 expression ranged from 1 to 12 (median 6.1), with
11/28 (39.3%) cases considered positive.
The expression of ALDH1 was cytoplasmic in carcin-
oma cells (Figure 1F). The IRS of the cancer cells with
cytoplasmic ALDH1 expression ranged from 1 to 12
with a median value of 5.6. Of the 28 cases, 13 (46.4%)
were considered positive.
Response analysis
As shown in Table 3, a positive CD44 expression was
found in 14 of the 17 cases (82.4%) in the NACRT group
and in 2 of the 11 cases (18.2%) in the non-NACRT
group; the difference between the two groups was sig-
nificant (P = 0.00148).
Positive CD133 expression was found in 5 of the 17
cases (29.4%) in the NACRT group and in 9 of the 11eatic adenocarcinoma. The arrows indicate strong staining intensity
cale bar, 100 μm.
Table 3 Frequency of CSCs markers positive cases
NACRT(n = 17) Non-NACRT(n = 11) P-value
EpCAM(+) 58.8% 45.5% 0.700
CD24(+) 35.3% 36.4% 1.000
CD44(+) 82.4% 18.2% 0.00148
CD133(+) 29.4% 81.8% 0.0183
CXCR4(+) 47.1% 27.2% 0.435
ALDH1(+) 64.7% 18.2% 0.0237
Fisher’s exact test.
The bold value indicates a statistically significant result.
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between the two groups was significant (P = 0.0183).
Positive ALDH1 expression was found in 11 of the 17
cases (64.7%) in the NACRT group and in 2 of the 11
cases (18.2%) in the non-NACRT group; the difference
between the two groups was significant (P = 0.0237).
No significant differences were found in the frequency
of expression of EpCAM, CD24 or CXCR4 between the
NACRT group and the non-NACRT group.
Correlation among CSC markers
As shown in Table 4, CD133 expression was inversely
related to ALDH1 expression in the NACRT group
(P = 0.0276), but no significant associations were ob-
served between the other CSCs markers.
Association with histopathological variables
Table 5 shows the associations of CSC markers with clini-
copathologic features in the NACRT group. The positiveTable 4 Correlations between CSC marker expressions in the
ESA CD24
(+) (-) P (+) (-) P (+)
CD24
(+) 4 2 1.000
(-) 6 5
CD44
(+) 9 5 0.537 4 10 0.515
(-) 1 2 2 1
CD133
(+) 3 2 1.000 3 2.280 5 0
(-) 7 5 3 9 9 3
CXCR4
(+) 4 4 0.637 4 4 0.335 6
(-) 6 3 2 7 8
ALDH1
(+) 7 4 0.644 3 8 0.600 9
(-) 3 3 3 3 5
Fisher’s exact test.
The bold value indicates a statistically significant result.expression of CXCR4 was significantly correlated with a
higher liver metastasis rate (P = 0.0152).
Positive CD133 and negative ALDH1 expression had a
markedly poorer OS
Figure 2 shows that the patients who underwent NACRT
had significantly better disease-free survival (DFS) and over-
all survival (OS) rates compared to the patients who did not
undergo NACRT (P = 0.0056 and P = 0.0158, respectively).
In the NACRTgroup, the patients with positive CD133 ex-
pression had a significantly poorer OS rate (P = 0.0406) com-
pared to those with negative CD133 expression (Figure 3A).
However, the patients with positive expression of CD44
and ALDH1 had no significant differences in prognosis
compared to the patients with negative expression of
CD44 and ALDH1. In addition, the patients with positive
CD133 and negative ALDH1 expression had a markedly
poorer OS rate (P = 0.0039) compared to the patients with
expressions of other markers (Figure 3B).
Discussion
In this study, we focused on EpCAM, CD24, CD44,
CD133, CXCR4 and ALDH1 as representative pancreatic
CSC markers and examined the effect of NACRT on
pancreatic CSCs. Our major findings are as follows:
(1) CD44- and ALDH1-positive cells may have chemora-
diation resistance, but CD133-positive cells may have
chemoradiation susceptibility in pancreatic cancer;
(2) CD133 and ALDH1 expressions may be useful predic-
tors of prognosis in pancreatic adenocarcinoma patients
who have received NACRT. As the evaluation method ofNACRT group
CD44 CD133 CXCR4
(-) P (+) (-) P (+) (-) P
0.515
2 0.576 2 6 1.000
1 3 6
2 1.000 1 10 0.0276 5 6 1.000
1 4 2 3 3













Parameter Total (n = 10) p (n = 6) p (n = 14) p (n = 5) p (n = 8) p (n = 11) p
Histological classification
Grade 1/2 11 8 0.186 4 0.547 9 1.000 4 0.0801 3 0.0633 8 0.547
Grade 3 5 2 1 4 0 4 3
ungradeable 1 0 1 1 1 1 0
ypT
ypT2 1 1 1.000 0 1.000 1 1.000 0 1.000 0 1.000 1 1.000
ypT3 16 9 6 13 5 8 10
ypN
ypN1 4 3 0.603 2 0.584 3 1.000 2 0.538 2 1.000 3 1.000
ypN0 13 7 4 11 3 6 8
Tumour down stage
Present 5 4 0.338 2 1.000 5 0.515 1 1.000 4 0.131 3 1.000
Absent 12 6 4 9 4 4 8
Lymphatic invasion
Present 1 0 1.000 0 1.000 1 1.000 0 1.000 0 1.000 1 1.000
Absent 16 10 6 13 5 8 10
Blood vessel invasion
Present 11 7 0.644 3 0.600 9 1.000 3 1.000 4 0.335 7 1.000
Absent 6 3 3 5 2 4 4
Perineural invasion
Present 12 6 0.338 3 0.280 10 1.000 3 0.600 6 1.000 8 1.000
Absent 5 4 3 4 2 2 3
Recurrence
Present 11 6 1.000 5 0.333 10 0.515 4 0.600 7 0.131 7 1.000
Absent 6 4 1 4 1 1 4
Liver metastasis
Present 7 3 0.350 3 0.644 6 1.000 2 1.000 6 0.0152 6 0.304
Absent 10 7 3 8 3 2 5
Tumor destruction (Evans’s
criteria)
I/lla 8 5 1.000 1 0.131 7 1.000 1 0.294 3 0.637 5 1.000
llb/lll 9 5 5 7 4 5 6
Fisher’s exact test.
The bold value indicates a statistically significant result.
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several CSC markers immunohistochemically detected
in human pancreatic cancer specimens from patients
who received and did not receive NACRT. Although
the comparison of tissue samples obtained from the
same individual before and after NACRT is desirable, the
evaluation has been difficult in terms of the quantity and
quality of biopsy material before NACRT. Thus, we
think that comparisons between patients in similar
cohorts who received and did not receive NACRT areadequate to determine whether the survival of CSC
marker-positive cells is a phenomenon that occurs in
human cancer tissue.
Regarding the chemoradiation resistance to pancreatic
CSCs, we have demonstrated that the frequencies of
CD44- and ALDH1-positive cases are increased in the
NACRT group. This result indicates that CD44- and
ALDH1-positive cells may have chemoradiation resist-
ance in pancreatic cancer. CD44 is involved in cell-



















































Figure 2 Prognostic analysis of NACRT. A: Disease-free survival (DFS) of the patients stratified by the treatment method. The DFS of the patients with
NACRT was significantly better than that of the non-NARCT patients (median DFS 12.6 mos for the NACRT group vs. 4.3 mos for the non-NACRT group;
P = 0.0056). B: Overall survival (OS) for patients stratified by the treatment method. The OS of the NACRT group was significantly better than that of the
non-NACRT group (median OS 26.8 mos for the NACRT group vs. 10.8 mos for the non-NACRT group; P = 0.0158).
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http://www.biomedcentral.com/1471-2407/14/687as a CSC marker in cancers of the head and neck [22],
breast [30] and prostate [31]. Similar to our results,
Tajima et al. [10] showed the frequencies of CD44- posi-
tive cases were increased after gemcitabine-based neoadju-
vant chemotherapy and concluded CD44- positive cells






















Time after surgery (month)
P=0.0406, Log-rank test
A OS
Figure 3 Positive CD133 expression correlates with poor prognosis in
their CD133 expression status. The OS of the patients with positive CD133
negative CD133 expression (median OS 17.6 mos for those showing positiv
expression; P = 0.0406). B: Overall survival for the NACRT patients stratified
with CD133+/ALDH1− was significantly worse than that of the patients wit
showing CD133+/ALDH1− vs. 31.8 mos for those showing the other markeALDH1 is an intracellular enzyme involved in retinoic
acid, and it has been characterized as a CSC marker in
different types of cancer of the head and neck [22],
breast [30], lung [32], and colon [33]. In pancreas can-
cer, ALDH1 was associated with high turmorigenic can-






















Time after surgery (month)
P=0.0039, Log-rank test
B OS
the NACRT group. A: The OS of the NACRT patients stratified by
expression was significantly worse than that of the patients with
e CD133 expression vs. 41.1 mos for those showing negative CD133
by their CD133 and ALDH1 expression status. The OS of the patients
h the other markers’ expressions (median OS 12.1 mos for those
rs’ expressions; P = 0.0039).
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chemical studies examined the prognostic significance of
ALDH1 in pancreatic cancer, but their results conflict,
perhaps because the evaluation methods differed (using
tissue microarrays [15] vs. whole-mount tissue slides [16]).
Moreover, there were also no immunohistochemical stud-
ies about the chemoradiation resistance. Our finding is a
first report indicating that ALDH1-positive cells might be
resistant to chemoradiation therapy.
On the other hand, our results have also showed that
CD133-positive cells may have chemoradiation suscepti-
bility. CD133 is a cell surface glycoprotein that has been
widely used as a marker for CSCs in various types of
solid tumours and it has been believed that the CD133-
positive cells had chmoradiation resistance [36].
One of the reasons why our data are different from
published literature may be related to the antibodies we
used and the number of cases, as well as to the influence
of NACRT.
Also, this conflicting result can be explained under the
assumption that not all CD133-positive cells are charac-
terized as the same cell population, and not all these
cells are resistant to chemoradiation. It may be that clo-
nogenicity varies among cancer cells bearing distinct
cancer stem cell markers, and so does their sensitivity to
altered fractionation. In fact, it has been reported re-
garding the susceptibility of CD133-positive cells for
chemoradiation in gastric [37] and colon cancer [38].
Additional study in larger cohorts and basic research are
required to clarify this result.
Regarding the prognosis in the NACRT group, there
are no significant differences in DFS (Additional file 1:
Figure S1) and OS (Additional file 2: Figure S2) in
almost all CSCs marker expect CD133. Despite CD133-
positive cells apparently may have chemoradiation sus-
ceptibility, this data is consistent with the results that
the expression CD133-positive cells in pancreatic cancer
without NACRT related to poor clinical outcome [12,13].
Thus, CD133 expression has a possibility to influence the
prognosis on pancreatic cancer regardless of the presence
or absence of NACRT. Furthermore, our results suggest
that NACRT might reduce the frequency of CD133 ex-
pression and subsequently result in patient’s favorable
prognosis in pancreatic cancer.
With respect to the CSCs markers expression, there
were almost all no associations among the co-expression
of different CSCs markers used in our study. Interestingly,
although its significance is unknown, CD133 expression
was inversely related to ALDH1 expression after NACRT,
and the patients with positive CD133 and negative
ALDH1 expression had a markedly poorer OS rate com-
pared to the other patients. A similar result was reported
for head and neck cancer treated with chemoradiation, in
which positive CD44 and negative ALDH1 expression waslinked with significantly poor prognosis [22]. ALDH1 is
an enzyme that is required for the conversion of retinol
(vitamin A) to retinoic acids and retinoic acid is related
to the differentiation of cells, so inhibition of ALDH1
delayed the differentiation of human hematopoietic
stem cells [39].
We speculate the expression of ALDH1 is also related
to the differentiation of cancer stem cells.
As a result, combination with several stem cell markers
may become a more powerful prognosis prediction marker.Conclusions
We found that CD44- and ALDH1-positive expressions
were more common in the NACRT group than in the
non-NACRT group, whereas CD133-positive expression
was found to be common in the non-NACRT group. In
addition, CD133+ expression and CD133+/ALDH1− ex-
pression were associated with a poor outcome in the
NACRT group. CD133 and ALDH expressions are use-
ful predictors of prognosis in PA patients who have re-
ceived NACRT.
However, our results were obtained in a small cohort
(n = 28) of PA patients, and additional studies in larger
cohorts are required to clarify the predictive signifi-
cance, if any, of the expressions of CSCs markers in
pancreatic cancer.Additional files
Additional file 1: Figure S1. Significance of the CSCs markers in
Disease-free survival (DFS) in the NACRT group. The DFS of the NACRT
patients stratified by their CSCs marker expression status. There are no
significant differences in DFS in all CSCs marker.
Additional file 2: Figure S2. Significance of the CSCs markers in
Overall survival (OS) in the NACRT group. The OS of the NACRT patients
stratified by their CSCs marker expression status. There are no significant
differences in OS in almost allCSCs marker expect CD133.Abbreviations
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